Vortex Energy Quote - VRTX

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.045

Bid

0.045

Ask

0.05

Volume

27,000

0.045 Day's Range 0.05

0.045 52 Week Range 0.85

Previous Close

0.045

Open

0.05

Last Trade

10000

0.045

Last Trade Time

Average Volume (3m)

127,028

Financial Volume

VWAP

Vertex Pharmaceuticals Announces the Date of its Third Quarter 2006 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 9 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will announce its third quarter 2006 financial results on Thursday, October 26, 2006...

Vertex Pharmaceuticals Announces Completion of Common Stock Offering

CAMBRIDGE, Mass., Sept. 20 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common...

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences

CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) will webcast corporate presentations at Merrill Lynch's Global Pharmaceutical, Biotech...

Vertex Pharmaceuticals Announces Pricing of Common Stock Offering

CAMBRIDGE, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common...

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680

Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 WHITEHOUSE STATION, N.J. and CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Merck & Co., Inc...

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor

Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- Encouraging Results Support...

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC

Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC BANGKOK, Thailand, July 13 /PRNewswire-FirstCall/ -- The protease inhibitor (PI) LEXIVA(R...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.005	-10	0.05	0.05	0.045	129425	0.04539791	CS
4	-0.01	-18.1818181818	0.055	0.055	0.045	120734	0.04754326	CS
12	-0.07	-60.8695652174	0.115	0.115	0.045	127028	0.06523243	CS
26	-0.18	-80	0.225	0.235	0.045	97414	0.0986682	CS
52	-0.385	-89.5348837209	0.43	0.85	0.045	159641	0.35329509	CS
156	-0.055	-55	0.1	2.32	0.045	196471	0.90039976	CS
260	-0.055	-55	0.1	2.32	0.045	196471	0.90039976	CS

VRTX - Frequently Asked Questions (FAQ)

What is the current Vortex Energy share price?

The current share price of Vortex Energy is $ 0.045

What is the 1 year trading range for Vortex Energy share price?

Vortex Energy has traded in the range of $ 0.045 to $ 0.85 during the past year

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CNTRCENTR Brands Corp	$ 0.15 (114.29%)	31.1k
BEEBee Vectoring Technologies International Inc	$ 0.01 (100.00%)	108.8k
AWRAurwest Resources Corporation	$ 0.01 (100.00%)	20k
WINCommon Stock	$ 0.015 (50.00%)	2.6k
RXMRockex Mining Corporation	$ 0.015 (50.00%)	1.73k
HROHero Innovation Group Inc	$ 0.005 (-66.67%)	100k
NXU.XNexco Resources Inc	$ 0.005 (-50.00%)	4k
PUMPStock Trend Capital Inc	$ 0.005 (-50.00%)	193.1k
WBIOWPD Pharmaceuticals Inc	$ 0.01 (-50.00%)	119k
AUMCAuric Minerals Corp	$ 1.72 (-43.23%)	566.38k
QIMCQuebec Innovative Materials Corp	$ 0.08 (-11.11%)	2.63M
SOLSOL Global Investments Corp	$ 0.38 (4.11%)	976.71k
NUENU E Power Corp	$ 0.35 (7.69%)	923.5k
IDKThreeD Capital Inc	$ 0.165 (-10.81%)	854.58k
SPODSpod Lithium Corp	$ 0.03 (-14.29%)	822.58k